That's not to mention potential gene therapy threats. For both Adakveo and Oxbryta, 64% of physicians said the drugs have unfavorable cost and ...
https://www.google.com/url?rct=j&sa=t&url=https://www.fiercepharma.com/pharma/novartis-gbt-sickle-cell-disease-drugs-face-coverage-hurdles-as-doctors-spot-gene-therapy&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AFQjCNGxCCbjDT1OnxqCa8PeM80y619ivQ
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.